- Home
- BOLT vs LPCN Comparison
BOLT vs LPCN Comparison
Compare BOLT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- LPCN
- Stock Information
- Founded
- BOLT 2015
- LPCN 1997
- Country
- BOLT United States
- LPCN United States
- Employees
- BOLT N/A
- LPCN N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- LPCN Health Care
- Exchange
- BOLT Nasdaq
- LPCN Nasdaq
- Market Cap
- BOLT 16.8M
- LPCN 16.1M
- IPO Year
- BOLT 2021
- LPCN N/A
- Fundamental
- Price
- BOLT $5.65
- LPCN $3.00
- Analyst Decision
- BOLT Buy
- LPCN Strong Buy
- Analyst Count
- BOLT 3
- LPCN 2
- Target Price
- BOLT $50.00
- LPCN $9.00
- AVG Volume (30 Days)
- BOLT 20.2K
- LPCN 29.3K
- Earning Date
- BOLT 08-12-2025
- LPCN 08-07-2025
- Dividend Yield
- BOLT N/A
- LPCN N/A
- EPS Growth
- BOLT N/A
- LPCN N/A
- EPS
- BOLT N/A
- LPCN N/A
- Revenue
- BOLT $3,638,000.00
- LPCN $3,674,834.00
- Revenue This Year
- BOLT N/A
- LPCN N/A
- Revenue Next Year
- BOLT $24.14
- LPCN N/A
- P/E Ratio
- BOLT N/A
- LPCN N/A
- Revenue Growth
- BOLT N/A
- LPCN N/A
- 52 Week Low
- BOLT $5.20
- LPCN $2.68
- 52 Week High
- BOLT $15.60
- LPCN $7.61
- Technical
- Relative Strength Index (RSI)
- BOLT 47.50
- LPCN 40.07
- Support Level
- BOLT $5.68
- LPCN $3.10
- Resistance Level
- BOLT $6.40
- LPCN $3.39
- Average True Range (ATR)
- BOLT 0.27
- LPCN 0.18
- MACD
- BOLT 0.07
- LPCN -0.00
- Stochastic Oscillator
- BOLT 50.00
- LPCN 0.00
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.